Biopharma must learn from COVID-19 and make sure it has capacity to respond to future pandemics, according to biobanking firm GoodCell. SARS-CoV-2 has killed more than 1.6 million people worldwide and sickened millions more in the 12 months since it was first detected. The virus has disrupted almost every industry and prompted Governments to introduce strict measures to try and slow its spread. But the virus has also been a catalyst for innovation. From the use of internet conference technologies…